Introdução: O 18 F-fluorodesoxiglucose-tomografia por emissão de pósitrons/tomografia computorizada tem sido aplicado ao estudo da atividade metabólica e da inflamação do tecido adiposo, constituindo uma possível ferramenta para complementar a estratificação de risco na obesidade. Os objetivos deste estudo foram a avaliação da captação de 18 F-fluorodesoxiglucose pelo tecido adiposo visceral e pelo tecido adiposo subcutâneo e a determinação de eventuais diferenças em doentes com e sem obesidade. Material e Métodos: Estudo retrospetivo de doentes adultos submetidos a 18 F-fluorodesoxiglucose-tomografia por emissão de pósi-trons/tomografia computorizada entre julho e agosto de 2016. Análise estatística: software SPSS™ versão 20. Significância estatística: p < 0,05.
INTRODUCTION
Adipose tissue is an active endocrine organ with a central role in lipid and glucose metabolism. It produces a large number of hormones and cytokines involved in the development of metabolic syndrome, diabetes mellitus and vascular diseases. 1 The overall adiposity excess is associated with cardiovascular morbidity and mortality but Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com
Monteiro AM, et al. Metabolic activity in the visceral and subcutaneous adipose tissues, Acta Med Port 2017 Nov;30 (11):813-817 the different distribution of fat depots is associated with differential metabolic risk. It is well established that increased visceral adipose tissue (VAT) is strongly correlated with an adverse metabolic risk profile. By contrast, the increased subcutaneous adipose tissue (SAT) seems to have less importance on adverse risk profile. [2] [3] [4] The differences between VAT and SAT concerning secretion of inflammatory mediators, gene expression and cell morphology have already been documented. Recently, 18 F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) combined with computed tomography (CT) imaging has been used for the study of glucose metabolic activity and inflammation in adipose tissue. It has been demonstrated that metabolic activity in the VAT and SAT might be differentially regulated and FDG-PET/CT imaging could be a reliable tool for evaluating this parameter and to complement the cardiometabolic risk calculation. 5, 6 The aims of this study were the evaluation of the uptake of FDG by VAT and SAT and to determine differences in patients with and without obesity who underwent whole body 18 FDG-PET/CT scanning for clinical purposes (cancer diagnosis or staging).
MATERIALS AND METHODS

Subjects and protocol
We retrospectively analyzed 156 consecutive adult patients who underwent whole body 18 FDG-PET/CT scanning for clinical purposes (diagnosis or staging of cancer) between July and August of 2016.
Information regarding diabetes (medical history of diabetes and/or medication), hypertension and dyslipidemia was obtained from medical records.
Weight and height were self-reported and thereafter BMI (body mass index) was calculated. Obesity was considered in patients with a BMI greater than 30 kg/m 2 . Abdominal circumference from cross-sectional CT image was measured using the software recommended by the National Institutes of Health -ImageJ. 7 After fasting for six hours, the patients received FDG intravenously (if blood glucose was ≤ 250 mg/dL). Whole body images were acquired on a PET/CT scanner (Siemens Biograph 6) 50 to 90 minutes after tracer administration. Low-dose, non-contrast CT scan was performed for attenuation correction and anatomical localization. PET scan was acquired in 3-dimensional mode from base of skull to mid-thigh. Siemens Syngo MI Applications VA60A software was used for image analysis.
Regions of interest (ROIs) in VAT (epiploon), SAT (L3 level), liver (right hepatic lobe), psoas muscle and myocardium were drawn and the intensity of FDG uptake (maximum and mean SUV) was analyzed in these locations. Also, to determine the density of VAT and SAT, the Hounsfield units (HU) were recorded.
Statistical analysis
Normal distribution of the variables was evaluated through histogram. Continuous variables were expressed as mean and standard deviation or as median and interquartile range (IQR). Categorical variables were expressed as frequencies and percentages. Group comparisons were made using the t test or Mann-Whitney U test for continuous variables and the chi-square (χ 2 ) test for categorical variables. Linear regression analysis was performed to identify independent parameters associated with the mean FDG uptake in VAT and SAT. Statistical significance was defined at p < 0.05. All statistical analysis was performed using SPSS™ software version 20.
RESULTS
The mean age of the 156 patients was 61.0 ± 14.1 years and there was a predominance of males (n = 91; 58.3%). Half of the patients (n = 78; 50%) were overweight [body mass index (BMI) ≥ 25.0 kg/m 2 ] and 15.4% (n = 24) were considered obese (BMI ≥ 30 kg/m 2 ). The detailed clinical characteristics of the study population are presented in Table 1 .
The study population was divided in two groups (obese and non-obese) with similar age and gender distribution. Differences in clinical characteristics and FDG uptake values between the groups are represented in Table 2 .
The mean FDG uptake was higher in VAT than in SAT in both groups (0.5 vs 0.26; p < 0.001 and 0.6 vs 0.28; p < 0.001, obese and non-obese patients respectively). There were no differences in FDG uptake in VAT (mean and maximum SUV) between the groups.
Obese patients had higher maximum FDG uptake (0.7 vs 0.6; p = 0.02) but lower mean FDG uptake (0.26 vs 0.28; p = 0.008) in SAT. Also, this group had higher FDG uptake in liver (2.4 vs 2.1; p = 0.001) and in muscle (0.9 vs 0.7; p < 0.001).
We observed lower density, determined by HU, of VAT (-101.9 vs -93.4; p < 0.001) and SAT (-111.5 vs -106.5; p = 0.008) in obese patients. Table 3 and 5 shows the coefficients of correlation (Spearman correlation) between the mean uptake in VAT and in SAT, respectively, and the different studied variables. Subsequently, a multiple linear regression analysis was performed to identify independent parameters associated with the mean FDG uptake in VAT [F (4, Tables 4 and 6 , respectively). We found that the abdominal circumference and the density of VAT had a positive predictive value in the mean FDG uptake in VAT. In SAT, higher BMI and maximum uptake in myocardium were independent and negatively associated with the mean FDG uptake. Density of SAT and VAT and mean uptake in muscle had a positive predictive value in the mean uptake in SAT.
DISCUSSION
Our study demonstrated a higher FDG uptake in VAT, comparatively to SAT, in both obese and non-obese patients. Similar findings were reported by other authors, and it is assumed to be correlated to a higher metabolic activity in VAT. Furthermore, this difference could reflect the different profile of inflammatory mediators secreted between the two adipose tissues, supporting the concept that VAT is more strongly correlated with adverse metabolic profile risk. 5, [8] [9] [10] [11] Notwithstanding the known link between obesity and inflammation, there were no differences in FDG uptake in VAT between patients with or without obesity. This result is in conformity with Christen et al, but in contrast with the results of Oliveira et al, where obese patients had higher FDG uptake in VAT. 5, 10 We found a positive and independent association between abdominal circumference and mean FDG uptake in VAT. However, BMI was not associated with the mean FDG uptake in VAT. Those observations support the fact that adipose tissue distribution might have a more important role than excess adiposity per se in metabolic risk stratification.
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In concordance with Rosenquist et al, obese patients had lower density of VAT and SAT. It is known that the lower density is a marker of a more lipid dense and less vascularity of fat tissue. Rosenquist et al have also found that a lower CT attenuation (measured in HU) in VAT and in SAT was correlated with higher BMI. Moreover, the lower density of VAT and SAT was associated with a more adverse cardiometabolic risk. 13 Besides, our regression analysis demonstrated that density in VAT and in SAT were independent and positively associated with uptakes in VAT and in SAT, supporting the concept that higher density is associated with higher metabolic activity.
Remarkably, obese patients had higher maximum FDG uptake but lower mean FDG uptake in SAT. Also, in the regression analysis, higher BMI was independently associated with lower mean FDG uptake in SAT. As higher BMI is associated with lower density of adipose tissue, the lower density in obese patients could explain the lowering effect in the mean FDG uptake.
Similar to the study of Oliveira et al, we observed higher with better correlation and explanation of our findings. Finally, this was a retrospective study and we lacked the fasting lipid profile, insulin levels and indices of inflammation that could complement the study.
CONCLUSION
A non-invasive 18 FDG-PET/CT scanning allowed us to demonstrate significant differences between SAT and VAT metabolic activity in both obese and non-obese patients.
According to our results, abdominal circumference is an important determinant in FDG uptake in VAT. We also demonstrated that obese patients had lower density which is a marker of a lipid-laden fat tissue and minor vascularity. Our findings reinforce the importance of the adipose tissue quality and distribution for metabolic risk stratification.
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